Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Proteflazid is a direct-acting antiviral herbal extract developed by Ecopharm. It is derived from wild cereals *Deschampsia caespitosa L.* (tufted hair grass) and *Calamagrostis epigeios L.* (bush grass) and contains flavonoid glycosides as its active components. The drug exerts its antiviral effect by inhibiting viral DNA polymerase and thymidine kinase, which are essential for the replication of both DNA and RNA viruses. Additionally, Proteflazid induces the synthesis of endogenous alpha- and gamma-interferons to physiologically active levels, thereby enhancing the host's non-specific immune response. It is indicated for a broad spectrum of viral infections, including herpes simplex virus (types 1-5), human papillomavirus (including oncogenic strains), hepatitis B and C, HIV/AIDS, influenza, and coronavirus (COVID-19). Formulated as oral drops, it has been approved for clinical use in Ukraine and other regions for patients of all ages, including newborns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Proteflazid.